Your browser doesn't support javascript.
loading
Polygenic risk modeling for prediction of epithelial ovarian cancer risk.
Dareng, Eileen O; Tyrer, Jonathan P; Barnes, Daniel R; Jones, Michelle R; Yang, Xin; Aben, Katja K H; Adank, Muriel A; Agata, Simona; Andrulis, Irene L; Anton-Culver, Hoda; Antonenkova, Natalia N; Aravantinos, Gerasimos; Arun, Banu K; Augustinsson, Annelie; Balmaña, Judith; Bandera, Elisa V; Barkardottir, Rosa B; Barrowdale, Daniel; Beckmann, Matthias W; Beeghly-Fadiel, Alicia; Benitez, Javier; Bermisheva, Marina; Bernardini, Marcus Q; Bjorge, Line; Black, Amanda; Bogdanova, Natalia V; Bonanni, Bernardo; Borg, Ake; Brenton, James D; Budzilowska, Agnieszka; Butzow, Ralf; Buys, Saundra S; Cai, Hui; Caligo, Maria A; Campbell, Ian; Cannioto, Rikki; Cassingham, Hayley; Chang-Claude, Jenny; Chanock, Stephen J; Chen, Kexin; Chiew, Yoke-Eng; Chung, Wendy K; Claes, Kathleen B M; Colonna, Sarah; Cook, Linda S; Couch, Fergus J; Daly, Mary B; Dao, Fanny; Davies, Eleanor; de la Hoya, Miguel.
  • Dareng EO; University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK.
  • Tyrer JP; University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, UK.
  • Barnes DR; University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK.
  • Jones MR; Center for Bioinformatics and Functional Genomics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Yang X; University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK.
  • Aben KKH; Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
  • Adank MA; Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
  • Agata S; The Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital, Family Cancer Clinic, Amsterdam, The Netherlands.
  • Andrulis IL; Veneto Institute of Oncology IOV-IRCCS, Immunology and Molecular Oncology Unit, Padua, Italy.
  • Anton-Culver H; Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for Cancer Genetics, Toronto, ON, Canada.
  • Antonenkova NN; University of Toronto, Department of Molecular Genetics, Toronto, ON, Canada.
  • Aravantinos G; University of California Irvine, Department of Epidemiology, Genetic Epidemiology Research Institute, Irvine, CA, USA.
  • Arun BK; N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.
  • Augustinsson A; 'Agii Anargiri' Cancer Hospital, Athens, Greece.
  • Balmaña J; University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston, TX, USA.
  • Bandera EV; Lund University, Department of Cancer Epidemiology, Clinical Sciences, Lund, Sweden.
  • Barkardottir RB; Vall d'Hebron Institute of Oncology, Hereditary cancer Genetics Group, Barcelona, Spain.
  • Barrowdale D; University Hospital of Vall d'Hebron, Department of Medical Oncology, Barcelona, Spain.
  • Beckmann MW; Rutgers Cancer Institute of New Jersey, Cancer Prevention and Control Program, New Brunswick, NJ, USA.
  • Beeghly-Fadiel A; Landspitali University Hospital, Department of Pathology, Reykjavik, Iceland.
  • Benitez J; University of Iceland, BMC (Biomedical Centre), Faculty of Medicine, Reykjavik, Iceland.
  • Bermisheva M; University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, UK.
  • Bernardini MQ; University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, Erlangen, Germany.
  • Bjorge L; Vanderbilt University School of Medicine, Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Black A; Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain.
  • Bogdanova NV; Spanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, Spain.
  • Bonanni B; Ufa Federal Research Centre of the Russian Academy of Sciences, Institute of Biochemistry and Genetics, Ufa, Russia.
  • Borg A; Princess Margaret Hospital, Division of Gynecologic Oncology, University Health Network, Toronto, ON, Canada.
  • Brenton JD; Haukeland University Hospital, Department of Obstetrics and Gynecology, Bergen, Norway.
  • Budzilowska A; University of Bergen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, Bergen, Norway.
  • Butzow R; National Cancer Institute, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA.
  • Buys SS; N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.
  • Cai H; Hannover Medical School, Department of Radiation Oncology, Hannover, Germany.
  • Caligo MA; Hannover Medical School, Gynaecology Research Unit, Hannover, Germany.
  • Campbell I; IEO, European Institute of Oncology IRCCS, Division of Cancer Prevention and Genetics, Milan, Italy.
  • Cannioto R; Lund University and Skåne University Hospital, Department of Oncology, Lund, Sweden.
  • Cassingham H; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
  • Chang-Claude J; Maria Sklodowska-Curie National Research Institute of Oncology, Department of Pathology and Laboratory Diagnostics, Warsaw, Poland.
  • Chanock SJ; University of Helsinki, Department of Pathology, Helsinki University Hospital, Helsinki, Finland.
  • Chen K; Huntsman Cancer Institute, Department of Medicine, Salt Lake City, UT, USA.
  • Chiew YE; Vanderbilt University School of Medicine, Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Chung WK; University Hospital, SOD Genetica Molecolare, Pisa, Italy.
  • Claes KBM; Peter MacCallum Cancer Center, Melbourne, VIC, Australia.
  • Colonna S; The University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, VIC, Australia.
  • Cook LS; University Medical Center Hamburg-Eppendorf, Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), Hamburg, Germany.
  • Couch FJ; National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, USA.
  • Daly MB; Tianjin Medical University Cancer Institute and Hospital, Department of Epidemiology, Tianjin, China.
  • Dao F; The University of Sydney, Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia.
  • Davies E; Westmead Hospital, Department of Gynaecological Oncology, Sydney, NSW, Australia.
  • de la Hoya M; Columbia University, Departments of Pediatrics and Medicine, New York, NY, USA.
Eur J Hum Genet ; 30(3): 349-362, 2022 03.
Article en En | MEDLINE | ID: mdl-35027648
ABSTRACT
Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, "select and shrink for summary statistics" (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI 1.28-1.48, AUC 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI 1.08-1.19, AUC 0.538) in women of East Asian ancestries; 1.38 (95% CI 1.21-1.58, AUC 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI 1.29-1.43, AUC 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI 1.35-1.64, AUC 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias de la Mama Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Neoplasias de la Mama Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Año: 2022 Tipo del documento: Article